Cynosure, Inc. received Health Canada Authorization to Market SculpSure® for non-invasive lipolysis of the abdomen and flanks.

SculpSure is a fat-reduction laser intended for individuals with a body mass index (BMI) of 30 or less.  The device can eliminate up to 24 percent of treated fat in a 25-minute procedure with no downtime, enabling patients to immediately return to their normal activities. The laser raises the temperature of body fat to disrupt and destroy those subcutaneous fat cells, which are then naturally eliminated over time and do not return.

"Health Canada's authorization of SculpSure signals another key regulatory milestone as we continue to broaden the availability of this breakthrough treatment platform to new geographic region,” says Cynosure President and CEO Michael Davin in a news release.